KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Coronavirus

Samsung Biologics Inks Deal to Mass-Produce COVID-19 Treatment

 1,757 total views,  1 views today

James Jung by James Jung
PUBLISHED: April 9, 2020 UPDATED: April 18, 2020
in Coronavirus, Samsung Biologics, South Korea, Virus
0
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.

Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.

Samsung Biologics announced on Thursday that it signed with Vir Biotechnology Inc. a manufacturing agreement worth approximately $362 million (438 billion won) to mass-produce COVID-19 treatment.

Under the deal, the Korean biopharmaceutical company would commence large scale manufacturing for Vir’s SARS-CoV-2 (COVID-19) monoclonal antibody (mAb) treatment. Samsung Biologics said it would start with technology transfer as early as October this year. The company would begin manufacturing potential commercial batches by 2021 at its Songdo plant in Incheon.

Vir Biotechnology, Inc. is a clinical-stage immunology firm based in San Francisco specializing in creating treatment drugs for infectious disease prevention. The bioscience company developed antibodies from blood samples from those completely cured of the SARS (Severe Acute Respiratory Syndrome) illness. Vir’s antibody candidate is said to be highly potent in neutralizing the SARS-CoV-2 in live-virus cellular assays.

The U.S. company aims to proceed directly into phase 2 of clinical trials within the next three to five months. The biological contract manufacturing organization (CMO) build’s on its letter of intent with Biogen, Inc. and previously announced CMO with WuXi Biologics.

The U.S. Food and Drug Administration (FDA) is currently reviewing to certify a fast-tracking the designation of the antibody as a possible therapy to cure coronavirus infected patients.

Antibody Therapeutics Global Potential

Dr. Tae Han Kim, CEO of Samsung Biologics, said that with Vir’s antibody candidate coupled with Samsung Biologics’ production scale has the potential to give hope to millions of people suffering from the effects of COVID-19.

George Scangos, CEO of Vir Biotechnology, expects that the world would significantly need antibody therapies given the trajectory of the COVID-19 pandemic. He added that Samsung Biologics share their commitment to work with exceptional speed in addressing the pandemic.

With the latest CMO, Vir hopes to secure a stable manufacturing site for its mass production of therapeutics antibody. Samsung Biologics expects the manufacturing agreement would raise its brand awareness in the international manufacturing market.

What’s your thoughts?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
Tags: antibodycoronavirusCOVID-19Samsung BiologicsSARS-CoV-2South Korea newstherapeuticstreatmentVir Biotechnology

Related Posts

South Korea gears up to bring World Expo 2030 to Busan
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

South Korea gears up to bring World Expo 2030 to Busan

March 11, 2023
Samsung headquarters
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

Korea’s top 100 companies’ economic contribution soar by 20%  in 9 years

July 20, 2022
South Korea curbs tech leaks to foreign countries
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

South Korea curbs tech leaks to foreign countries

February 8, 2022
Hyundai Rotem set to provide upgraded army tank variants to South Korea
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

Hyundai Rotem set to provide upgraded army tank variants to South Korea

February 2, 2022
S.Korea will track COVID-19 cases with AI-powered facial recognition from January
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

S.Korea will track COVID-19 cases with AI-powered facial recognition from January

December 14, 2021
South Korea sets site engineering standards for big tech firms
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
Google

South Korea sets site engineering standards for big tech firms

December 9, 2021
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • Robots to help Police Patrol in South Korea

    0 shares
    Share 0 Tweet 0
  • South Korea plans Urban Air Mobility Air Taxi services by 2025

    0 shares
    Share 0 Tweet 0
  • SK On to introduce South Korea’s first LFP Battery Prototype

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Outsourcing by Samsung to China Feared by Phone Parts Suppliers

    0 shares
    Share 0 Tweet 0
  • Netmarble subsidiary Metaverse Entertainment’s K-Pop virtual girl band MAVE has a smashing online debut

    0 shares
    Share 0 Tweet 0
  • KT Continues to Accelerate Its ‘Digico’ Transformation

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |